Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaAriela Noy, Robert Chen, Christopher R. Flowers et al.|Blood|2017Cited by 294
Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 StudyAriela Noy, Robert W. Chen, Sven de Vos et al.|Blood|2016Cited by 10